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INTRODUCTION 
The concept of hormesis, the stimulatory or adaptive responses to low doses, and 
nonlinear dose effects are becoming a more prominent and accepted concepts in 
toxicology and risk assessment (Calabrese, 2003). While many have contributed to 
the concepts in hormesis, its recent prominence is largely attributable to the 
detailed and extensive assessment of low-dose effects compiled by Ed Calabrese and 
Linda Baldwin. 
The road to the acceptance of hormesis has been a long and hard one. Most 
toxicologists have rejected the concept outright as irrelevant or simply ignored it or 
have simply been ignorant of the literature. The discovery that hornietic effects are 
evident in over 40% of all studies that meet the criteria for its existence, and that 
the effects are seen across toxins and phyla have indicated that low-dose stimulatory 
effects need to be seriously considered in toxicology and biology (Calabrese and 
Baldwin, 2001). 
However, what about clinical medicine? Hormesis is not as prominent a concept in 
pharmacology and medicine as the title of this jour~ial would indicate. Why is this? Is 
the concept of hormesis something only of value in toxicology aand risk assessment or 
are there wider implications? To answer this question I suggest that those interested 
in hormesis examine two areas of potential value - one area is new and largely 
unexamined, and the second is old and controversial. In examining these areas we 
should use research and data as the discerning factors and not make the n~istake of 
apn'on' rejection like others have applied to hormesis and that set it back for so long 
The first area is to examine if lowdose toxins can stimulate reparative processes 
such that they can used in the treatment of disease. The second is to examine the 
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effects of very low and ultralow dose stinrulatory effects. Two articles in this issue of 
Nvn-li.n,e(trily in Biology, l'oxicolo~gy and Medicine allow us to comment on these areas. 
CLINICAL RELEVANCE OF NONLINEAR EFFECTS 
Do nonlinear effects have important clinical implications? Toxins are not always 
poisons and drugs are sometimes toxic. For example, there are several hierarchical 
dose effects of aspirin, each with clinical implications. These include the differential 
effects of aspirin on serum thrornboxalre B2, gastric PGE2 output, and gastric 
mucosal injury with doses as low as 3 mg/day (Lee, 1994). Highdose aspirin 
increases bleeding time, but very low-dose aspirin (0.01 mg/day) shows a decrease 
in bleeding time (De Gaetano, 1988; Doutrernepuich, 1990). This effect is modu- 
lated by vascular wall endotheliulri factors, probably prostacyclin (PGI2) (Lalanne, 
1990). Some of these effects have gender differences. For example, bleeding time 
alrd platelet aggregation react differently in males and females at the same dose 
(Buchanan, 1983). High-dose and lnediu~ri dose aspirin are used clinically to inhibit 
platelet aggregation, but also can cause bleeding in the stomach and intestines. But 
do the hormetic effects of lowdose aspirin matter clinically? Could lowdose aspirin 
increase throinbotic events in men, say after surgery, and be used to prevent gastric 
bleeding from higher doses in both genders? More studies on the effects and 
inechallis~ns of low and very low doses of aspirin are needed before we can answer 
these questions, but their- answers could be breakthroughs in clinical medicine. 
Another example of the clinical utility of hormesis is the development of toler- 
ance. Celli~lar and tissue tolerance is a con~~rionly reported phenomenon in allergy 
desensitization. Could a similar effect be used in developing cellular tolerance to 
environmental toxins? In this issue, we report on the effects of low and ultralowdose 
exposure of normal prostate cells to low and ultralow doses of cadmium for up to 
20 weeks (Jonas, 2003). Expression of nletallothionein (MT), tlie primary Cd 
detoxification protein, was induced by exposure to lo-" MCd for over 20 weeks. Cd 
pretreated cells had delayed transformation compared to controls. In addition, the 
number of transformed cell mounds was lower in pretreated cells indicating that low 
and ultra-low dose exposure had protective effects to high-dose Cd induced carcine 
genesis. A11 exaggerated MT response remained even 4 weeks after growth in Cd 
free media. Thus, it appears that a prolonged protective window of resistance to 
cellular transformation was induced by exposure to low levels of Cd. The potential 
clinical utility of this is clear. If the induction of cellular tolerance is a general 
phenomenon (like hormesis) it may be a simple and safe mechanism for protection 
from a variety of environmental and perhaps even terrorist toxin exposures. This 
idea is certainly not any more unlikely than hormesis seemed a decade ago. 
HOW LOW DOES BIOLOGY GO? 
Do biological systems react to doses even lower than previously thought? One of 
the major obstacles to the acceptance of hormesis has been a disbelief that very low 
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doses can and do  have effects. Thankfi~lly, this concept is gradually eroding as good 
data accumulates showing otherwise. A second major obstacle to the exa~nination 
of the clinical utility of hormesis is the association of low-dose treatment with the 
controversial medical system called homeopathy. The contaminating use of the 
concept of hormesis by homeopathy in an attempt to legitimize itself has caused a 
backlash by those interested in the science of liormesis against examining ultralow 
doses effects (Calabrese, 2002). 
Misuse of the concept of hormesis by unscientific groups should not be the 
driving factor in looking at nonlinear dose effects. Those interested in the science 
of low-dose responses should not treat ultralow doses such as traditional pharrnacol- 
ogy has treated hormesis. Recent reviews of the clinical research on homeopathy 
have come to unclear conclusions (Jonas, 2003). Before throwing out the bathwater, 
let's find the baby first. While hormesis does not prove homeopathy, neither should 
a fear of homeopathy bias scientists against looking at very low doses. Good scientific 
methodology must remain the primary factor in determining truth, not fear of 
association. 
In our prostate cell model of low and ultralow-dose Cd we found that MT was 
not enhanced in doses below lo-" M. However, mRNA subtype MT-IG was up- 
regulated at much lower exposures, and this subtype correlated more closely with 
delayed transformation from high-dose Cd than any other factor. In a second 
article in this issue, Elibieta Malarczyk (2003) and colleagues report on the 
nonlinear effect of low-dose guaiacol and ethanol on the laccase and peroxidjse 
activities of two strains of Basidiomycetes, Plfurotus sajor-caju and Trarn~trs uc~rcicolor. 
Unlike in most studies, they continued to find nonlinear responses in dose ranges 
as low as mol/L. One of the three reviewers of this article called for outright 
rejection. The editors of this journal, however, decided to work closely with the 
authors to assure that their methodology was sound. After going through a 
meticulous checklist for quality (Table) that was ultimately answered adequately 
by the authors, it was decided to accept the article for publication. No doubt some 
readers will object to the publication of any research that claims to show effects 
below some predetermined level. However, if science is to prevail and if the 
potential clinical utility of hormesis is to be explored, we must guard against both 
poor methods and a priori conclusioiis. In all cases, however, research quality 
should be the primary judge of value if the clinical utility of horinesis is to be 
determined. 
We recommend that those doing research on hormesis, nonlinear effects in 
biological systems, and the protective or therapeutic effect of low-dose treatinelits 
begin with the quality criteria checklist in the Table of this editorial. We recognize 
that these criteria will evolve and change as the field matures. Indeed, other 
guidelines for quality research have also been published (Linde and Jonas, 1994; 
Jonas, 2001; Calabrese and Baldwin, 2001). We recommend these criteria as a 
starting point for investigators and reviewers when investigating the topic of protec- 
tive or therapeutic hormesis. 
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Table. Quality Evaluation Criteria for Studies on Low-Dose Effects 
Criteria Recommended Weight 
1. Experrmental Model and Study Design 
Adequate description of: 
- 
Experimental Model .......................... ------- - - - - - - .  1 
Homogeniety ............................. ------------- - ------------------ -- 1 
Sex (animaucell system) -- ------- ---- .................................... 1 
Laboratory conditions ------------------- ----------------- - --------- ------ 1 
Nutriti~dncubation ------------------------.------------------------------ 1 
Adaptation period (animal system) -- -------------- ----- 1 
Number per testfgroup ----- ------ --- -------- - ....................... ------ 2 
Randomization/matching -------------- ----- -- ------ -----..- -- ----- ---- 1 
2. Dilution and Dosing Preparation 
Qiluent--------------------------- ---- ------- - ---------- ----- 1 
Dilution ratio ---- ------- ................................................... -- 1 
Pharmacy/manufacturer ............................................ 1 
Handling bemeen dilution steps .................................... 2 
Contamination precaution ................................................. 2 
Verification of dose exposure 3 
Molw concentration -- .................................................... -- 2 
3. Control Groups 
Positive (high-dose) control ............................................... 3 
Negative (water or diluent) control ....................................... 3 
Untreated group (anjmal/cell system) .................................... 1 
Blinding ------------------em---------------- ------------ --------- ---- 2 
4. Pos01ogy - Adequate Description ofi 
Toxin and challenge dose .................................................. 2 
Outcome measurements .............................................. 1 
Validity of outcome measuements -------- ......................... ------ 2 
Intervention details (time, interval, volume, route, rate of exposure)- 1 
Time of day of intervention -------------- ............................. ----- 1 
Month of intervention ...................... --------- ----- ----- 1 
5. Atlalysis 
Appropriate statistical analysis (test and p. value) ...................... 3 
Details of results (n, m e w  s.d., ordinal numbers) ..................... 3 
6. Presentation of Results 
Background sufficient ..................... --------..- - ---------- ----- ------ 1 
Objectives defined ............................. -------- --------------------- 1 
Conclusions appropriate to data .............................. -------- 2 
Main shortcomings discussed -------- ---------------- ----------- ------ ----- 1 
Discussion addresses literame --- ------------------ -- -------- ------- - 1 -  
Total number of criteria ............................................... 32 
Total points possible .................... -------------- - --------- --- ---- ------ 50 
*Adapted from Linde and Jonas, 1994 
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